70 related articles for article (PubMed ID: 16520229)
1. Antiglioma activity of 2,2':6',2"-terpyridineplatinum(II) complexes in a rat model--effects on cellular redox metabolism.
Ahmadi R; Urig S; Hartmann M; Helmke BM; Koncarevic S; Allenberger B; Kienhoefer C; Neher M; Steiner HH; Unterberg A; Herold-Mende C; Becker K
Free Radic Biol Med; 2006 Mar; 40(5):763-78. PubMed ID: 16520229
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds.
Witte AB; Anestål K; Jerremalm E; Ehrsson H; Arnér ES
Free Radic Biol Med; 2005 Sep; 39(5):696-703. PubMed ID: 16085187
[TBL] [Abstract][Full Text] [Related]
3. Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase.
Gandin V; Fernandes AP; Rigobello MP; Dani B; Sorrentino F; Tisato F; Björnstedt M; Bindoli A; Sturaro A; Rella R; Marzano C
Biochem Pharmacol; 2010 Jan; 79(2):90-101. PubMed ID: 19665452
[TBL] [Abstract][Full Text] [Related]
4. Differential genomic and proteomic profiling of glioblastoma cells exposed to terpyridineplatinum(II) complexes.
Koncarevic S; Urig S; Steiner K; Rahlfs S; Herold-Mende C; Sueltmann H; Becker K
Free Radic Biol Med; 2009 Apr; 46(8):1096-108. PubMed ID: 19439228
[TBL] [Abstract][Full Text] [Related]
5. SC68896, a novel small molecule proteasome inhibitor, exerts antiglioma activity in vitro and in vivo.
Roth P; Kissel M; Herrmann C; Eisele G; Leban J; Weller M; Schmidt F
Clin Cancer Res; 2009 Nov; 15(21):6609-18. PubMed ID: 19825946
[TBL] [Abstract][Full Text] [Related]
6. The thioredoxin system in cancer.
Arnér ES; Holmgren A
Semin Cancer Biol; 2006 Dec; 16(6):420-6. PubMed ID: 17092741
[TBL] [Abstract][Full Text] [Related]
7. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy.
Tonissen KF; Di Trapani G
Mol Nutr Food Res; 2009 Jan; 53(1):87-103. PubMed ID: 18979503
[TBL] [Abstract][Full Text] [Related]
8. Cyclophosphamide as a potent inhibitor of tumor thioredoxin reductase in vivo.
Wang X; Zhang J; Xu T
Toxicol Appl Pharmacol; 2007 Jan; 218(1):88-95. PubMed ID: 17156807
[TBL] [Abstract][Full Text] [Related]
9. On the potential of thioredoxin reductase inhibitors for cancer therapy.
Urig S; Becker K
Semin Cancer Biol; 2006 Dec; 16(6):452-65. PubMed ID: 17056271
[TBL] [Abstract][Full Text] [Related]
10. Antiglioma activity of GoPI-sugar, a novel gold(I)-phosphole inhibitor: chemical synthesis, mechanistic studies, and effectiveness in vivo.
Jortzik E; Farhadi M; Ahmadi R; Tóth K; Lohr J; Helmke BM; Kehr S; Unterberg A; Ott I; Gust R; Deborde V; Davioud-Charvet E; Réau R; Becker K; Herold-Mende C
Biochim Biophys Acta; 2014 Aug; 1844(8):1415-26. PubMed ID: 24440405
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of thioredoxin reductase by mansonone F analogues: Implications for anticancer activity.
Liu Z; Huang SL; Li MM; Huang ZS; Lee KS; Gu LQ
Chem Biol Interact; 2009 Jan; 177(1):48-57. PubMed ID: 18822278
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity.
Lu J; Papp LV; Fang J; Rodriguez-Nieto S; Zhivotovsky B; Holmgren A
Cancer Res; 2006 Apr; 66(8):4410-8. PubMed ID: 16618767
[TBL] [Abstract][Full Text] [Related]
13. Human thioredoxin reductase is efficiently inhibited by (2,2':6',2' '-terpyridine)platinum(II) complexes. Possible implications for a novel antitumor strategy.
Becker K; Herold-Mende C; Park JJ; Lowe G; Schirmer RH
J Med Chem; 2001 Aug; 44(17):2784-92. PubMed ID: 11495589
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria.
Santos NA; Catão CS; Martins NM; Curti C; Bianchi ML; Santos AC
Arch Toxicol; 2007 Jul; 81(7):495-504. PubMed ID: 17216432
[TBL] [Abstract][Full Text] [Related]
15. Sublethal concentrations of diverse gold compounds inhibit mammalian cytosolic thioredoxin reductase (TrxR1).
Omata Y; Folan M; Shaw M; Messer RL; Lockwood PE; Hobbs D; Bouillaguet S; Sano H; Lewis JB; Wataha JC
Toxicol In Vitro; 2006 Sep; 20(6):882-90. PubMed ID: 16510263
[TBL] [Abstract][Full Text] [Related]
16. Transfer of 4'-chloro-2,2':6',2"-terpyridine platinum(II) between human serum albumin, glutathione and other thiolate ligands. A possible selective natural transport mechanism for the delivery of platinum(II) drugs to tumour cells.
Ross SA; Carr CA; Brïet JW; Lowe G
Anticancer Drug Des; 2000 Dec; 15(6):431-9. PubMed ID: 11716436
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the thioredoxin system is a basis for the antileukemic potential of 13-hydroxy-15-oxo-zoapatlin.
Nigro P; Dal Piaz F; Gallotta D; De Tommasi N; Belisario MA
Free Radic Biol Med; 2008 Sep; 45(6):875-84. PubMed ID: 18638547
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of thioredoxin reductase induces apoptosis in neuronal cell lines: role of glutathione and the MKK4/JNK pathway.
Seyfried J; Wüllner U
Biochem Biophys Res Commun; 2007 Aug; 359(3):759-64. PubMed ID: 17559804
[TBL] [Abstract][Full Text] [Related]
20. PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin.
Yuan Z; Yan F; Wang YS; Liu HY; Gou LT; Zhao XY; Lai ST; Deng HX; Li J; Ding ZY; Xiong SQ; Kan B; Mao YQ; Chen LJ; Wei YQ; Zhao X
Cancer Chemother Pharmacol; 2009 Dec; 65(1):13-25. PubMed ID: 19387645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
